iconoclast - After reviewing the contest tally on the 3rd page of the Link Library you seem to be getting more confident. You are now at $40 up from $25. 

When you review the charts in the Van Leeuwenhoeck Report which is at the top of the same page 3 in the in the Link Library the justification for $40 to $60 per share becomes quite easy if the BoM results come in at 40% RRR or better.

Personally I think the CKD and cognitive function trial results are going to have a positive impact that will stretch the upper limits but that's just my oppinion.

IMO even after making the adjustment for the royalty, an $8 to $15 billion market cap for RVX is justifiable if there is good success in all 3 categories being, 30% RRR or better for CVD, an increase in eGFR and an increase in cognitive function in those patients 70 and older on ABL.

All IMO, dyodd

tada